FDA Withdrawn Approval of Lymphoma Medicine Due to Safety Concerns
Stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine.
Summary
Ukoniq (umbralisib): Drug Safety Communication - FDA Approval of Lymphoma Medicine is Withdrawn Due to Safety Concerns
[Posted 3/Jun/2022]
AUDIENCE: Oncology
BACKGROUND Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma and follicular lymphoma.
RECOMMENDATIONS:
Health care professionals should stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine. In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access.
Patients should talk to your health care professionals about alternative treatments and stop taking Ukoniq. It is best to dispose of unused Ukoniq using a drug take-back location such as in a pharmacy, but if one is not available, you can dispose of Ukoniq in your household trash by doing the following:
Our Most Popular Resources
- Mix the medicine with an unappealing substance such as dirt, cat litter, or used coffee grounds; do not crush them.
- Place the mixture in a container such as a sealed plastic bag.
- Throw away the container in your home trash.
- Delete all personal information on the prescription labels of empty medicine bottles or packaging, then throw away or recycle them.
Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report online.
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.
Source: FDA Published: June 1, 2021
Single-Encounter Augmented Reality-Guided Localization for Resection of Suspected Early-Stage Lung Cancer
Single-encounter augmented reality (AR)-guided localization demonstrated noninferiority to conventional CT-guided localization for successful sublobar resection in patients with suspected early-stage lung cancer. The technique maintained procedural accuracy while reducing radiation exposure, procedure-related pain, and workflow duration, supporting its potential integration into minimally invasive thoracic surgical practice.
BACKGROUND: Suspected early-stage lung cancer often requires precise localization prior to resection. Traditional methods can result in multiple encounters and increased patient discomfort.
KEY FINDINGS: Using augmented reality-guided localization significantly reduced the number of encounters required and improved the accuracy of the resection margins.
DETAILS: In a recent trial involving 150 patients, single-encounter AR localization was compared against standard techniques. The AR group showed a 40% reduction in preoperative preparation time.
Our Most Popular Resources
Gadolinium-Based Contrast Agents: Reassessing Safety Beyond Nephrogenic Systemic Fibrosis
This review highlights that gadolinium-based contrast agents continue to play a critical role in diagnostic MRI, but their use should be guided by careful patient selection and individualized risk assessment. Although the risk of nephrogenic systemic fibrosis has declined considerably, further research is needed to clarify the clinical significance of gadolinium retention and its long-term safety.
Our Most Popular Resources
Optical Coherence Tomography Enables Optical Biopsy of Endometrial Tissue for Early Cancer Detection
Catheter-based 3D optical coherence tomography demonstrated high accuracy for distinguishing benign endometrium from endometrial intraepithelial neoplasia and endometrial cancer in this ex vivo study. The findings support its potential as a rapid, minimally invasive optical biopsy technique, although prospective in vivo validation is needed before clinical implementation.
Our Most Popular Resources
Promising Drug Candidates and Emerging Therapeutic Strategies Against Candida auris
Emerging therapies for Candida auris extend beyond conventional antifungal agents and include repurposed drugs, novel antifungal compounds, vaccines, antimicrobial peptides, and nanotechnology-based approaches. While further clinical validation is needed, these strategies may help address the growing challenge of multidrug-resistant C. auris infections.
Our Most Popular Resources
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts
Early initiation of a 5-day oral ensitrelvir regimen within 72 hours after symptom onset in an index patient significantly reduced the risk of developing Covid-19 among household contacts while maintaining a safety profile comparable to placebo. Clinical benefit was observed across major patient subgroups, including individuals at increased risk for severe disease, and treatment was associated with reduced household transmission. These findings support ensitrelvir as an effective postexposure prophylactic option for household contacts and suggest potential utility in other high-risk exposure settings where rapid outbreak control is needed.
Our Most Popular Resources
Specialty: